Overview

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-26
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen